-

Thermo Fisher Scientific and LabShares Partner to Support Emerging Boston Biotechs

Life science startups can accelerate early-stage discovery and development with state-of-the art technologies in shared lab spaces

WALTHAM, Mass.--(BUSINESS WIRE)--To support the Greater Boston biotech ecosystem, Thermo Fisher Scientific is joining forces with biotech incubator LabShares Newton to provide instruments, lab equipment and consumables to help early-stage life sciences companies accelerate their drug discovery efforts.

LabShares provides fully furnished lab space, services and equipment to more than 25 biotech companies, alleviating logistics constraints to help them bring novel therapeutics to market. Thermo Fisher will outfit the shared lab space with equipment including ultra-low temperature freezers, cell culture incubators, microscopes and PCR instruments.

“Thermo Fisher Scientific is incredibly excited to partner with LabShares in support of the emerging life science and biotech companies in Newton,” said Angela N. Hokanson, vice president, corporate accounts, Thermo Fisher Scientific. “In line with our mission to enable our customers to make the world healthier, cleaner and safer, we look forward to collaborating with LabShares and their members to innovate, validate and commercialize the next generation of life-saving therapies.”

“With little lab space available in historic biotech hubs such as Cambridge, emerging companies are looking to the suburbs for more accessible and affordable lab space,” said Jeff Behrens, CEO and founder, LabShares. “Working with partners such as Thermo Fisher allows LabShares to provide a caliber of equipment that smaller companies may not otherwise have access to, empowering promising biotech startups to hit the ground running.”

While investment in the biotech industry continues to climb, the high cost of bringing drugs through research and development to the market is limiting many early-stage companies from flourishing. By offering alternative lab space and more tailored support and resources, LabShares and its partners are helping emerging biotech companies clear hurdles that previously hindered growth for smaller companies trying to break through the market.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom